Vivofectamine™ VF232 Liver LNP Composition in Ethanol
Vivofectamine™ VF232 Liver LNP Composition in Ethanol
Invitrogen™

Vivofectamine™ VF232 Liver LNP Composition in Ethanol

Vivofectamine VF232 Liver LNP Composition in Ethanol is a reagent for use in the creation of lipid nanoparticles (LNPs) for in vivo delivery of mRNA or mRNA/gRNA via intravenous (IV) route to the liver.
Have Questions?
Catalog NumberQuantity
VF232LVCE1 mL
Catalog number VF232LVCE
Price (CLP)
1.695.270
1 mL
Add to cart
Quantity:
1 mL
Price (CLP)
1.695.270
1 mL
Add to cart
Vivofectamine VF232 Liver LNP Composition in Ethanol is a reagent for use in the creation of lipid nanoparticles (LNPs) for in vivo delivery of mRNA or mRNA/gRNA via intravenous (IV) route to the liver. It can be used for various basic research applications such as protein expression, protein replacement, and genome editing.

Features and benefits

  • Optimized formulation for systemic liver delivery
  • Delivery efficiency data in vivo benchmarked to ionizable lipids used in leading clinical-stage or FDA-approved drugs
  • Safety characterization in vivo
  • Flexibility in choice of formulation device and method

Vivofectamine VF232 Liver LNP Composition in Ethanol is a pre-mixed solution with an optimized ratio of an ionizable lipid and helper lipids. It can be used with various formulation devices and methods.

Vivofectamine VF232 Liver LNP Composition in Ethanol is a Research Use Only reagent for use in basic research. For an LNP solution for drug development purposes with a path to clinical and commercial licensing and supply, please submit a contact us request at our Vivofectamine webpage to access our Vivofectamine Delivery Solutions Drug Developers Portfolio.

Vivofectamine VF232 Liver LNP Composition in Ethanol is an animal origin-free product.

For Research Use Only. Not for use in diagnostic procedures.
Specifications
ClassificationAnimal origin-free (AOF)
Delivery TypeIn vivo
FormulationRatio-optimized mixture of lipid solution in ethanol
Product LineVivofectamine
Product TypeReagent
Quantity1 mL
Shipping ConditionDry Ice
SterilityNon-sterile
Sufficient ForEncapsulating up to 0.6 mg mRNA at N:P of 4 (yield is dependent on formulation process)
TargetLiver
FormatTube
SpeciesMouse
Transfection TechniqueLipid-based Transfection, Lipid Nanoparticles, LNPs
Unit Size1 mL

Frequently asked questions (FAQs)

Is Vivofectamine VF232 Liver LNP Composition in Ethanol reagent pre-formulated as lipid nanoparticles (LNPs?

No, Vivofectamine VF232 Liver LNP Composition in Ethanol reagent is in solution state and not preformulated as nanoparticles. The actual lipid nanoparticle (LNP) formation occurs during the mixing process with the nucleic acid solution. This approach allows for efficient encapsulation of the nucleic acid cargo in situ and enables the formation of stable, uniform nanoparticles.

Find additional tips, troubleshooting help, and resources within our Transfection Support Center.

How does lipid nanoparticle (LNP) delivery technology work?

Lipid nanoparticles (LNPs) utilize charge-based interactions between positively charged ionizable lipids at lower pH and negatively charged nucleic acids, for encapsulation of various types of nucleic acids (including mRNA, mRNA/sgRNA, siRNA, miRNA, ASO, and pDNA) within the LNP. The LNP protects the nucleic acid from degradation and facilitates its entry into cells. Once inside the cell, the nucleic acid is released into the cytoplasm, triggering the desired biological response.

Find additional tips, troubleshooting help, and resources within our Transfection Support Center.

Does quality of mRNA affect the characteristics of lipid nanoparticles (LNPs)?

The quality of mRNA itself does not typically directly affect the physical characteristics of lipid nanoparticles (LNPs), such as size, charge, or stability. However, it can significantly impact the overall performance and efficacy of the mRNA-LNP delivery system. mRNA quality can influence stability, translational efficiency, and immune response (toxicity). Please refer to the Vivofectamine user manual (https://assets.thermofisher.com/TFS-Assets/GSD/manuals/MAN0030062-vivofectamine-LNP.pdf) for recommendations.

Find additional tips, troubleshooting help, and resources within our Transfection Support Center.

How should I best handle Vivofectamine VF232 Liver LNP Composition in Ethanol reagent?

Vivofectamine VF232 Liver LNP Composition in Ethanol reagent should be stored at -80 degrees C. We recommend only one freeze-thaw for optimal results. If you plan to use smaller quantities multiple times, we recommend aliquoting the reagent when first thawed, based on your experimental needs, and storing the aliquots at -80 degrees C.

Find additional tips, troubleshooting help, and resources within our Transfection Support Center.

How should I measure safety of the mRNA-LNP (lipid nanoparticle) once administrated to animals?

To measure the safety of mRNA-LNPs after administration to animals, assess the following key parameters:
- Toxicology: Monitor for any signs of toxicity, including weight loss, behavioral changes, or adverse reactions.
- Histopathology: Examine tissues for any signs of inflammation, damage, or immune response.
- Biomarkers: Measure liver enzymes, cytokines, and other biomarkers to evaluate organ health and immune activation.
This guidance serves as a high-level overview for basic research. For drug development, please adhere to specific regulatory requirements and guidelines.

Find additional tips, troubleshooting help, and resources within our Transfection Support Center.

View all Vivofectamine™ VF232 Liver LNP Composition in Ethanol FAQs